Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
NCT ID NCT04935684
First seen Jun 13, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves survival without GvHD or relapse one year later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Département d'hématologie CAC Rouen
NOT_YET_RECRUITINGRouen, France
Contact
Contact
-
Hématologie clinique CHU Besançon
NOT_YET_RECRUITINGBesançon, France
Contact
Contact
-
Hématologie clinique Institut de Cancérologie de la Loire
NOT_YET_RECRUITINGSaint-Etienne, France
Contact
Contact
-
Hématologie clinique et thérapie cellulaire Hôpital Haut-Lévèque
NOT_YET_RECRUITINGPessac, France
Contact
Contact
-
IUC T - Oncopôle
NOT_YET_RECRUITINGToulouse, France
Contact
Contact
-
Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand
RECRUITINGClermont-Ferrand, France
Contact
Contact
-
Service Maladies du sang CHU Angers
NOT_YET_RECRUITINGAngers, France
Contact
Contact
-
Service d'Hématologie Adultes Hôpital Necker
RECRUITINGParis, France
Contact
Contact
-
Service d'Hématologie Centre Hospitalier Lyon Sud
NOT_YET_RECRUITINGLyon, France
Contact
Contact
-
Service d'Hématologie Clinique CHU Nantes
NOT_YET_RECRUITINGNantes, France
Contact
Contact
-
Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site Sud
NOT_YET_RECRUITINGAmiens, France
Contact
Contact
-
Service d'Hématologie clinique Hôpital Pitié-Salpêtrière
NOT_YET_RECRUITINGParis, France
Contact
Contact
-
Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU Nancy
NOT_YET_RECRUITINGNancy, France
Contact
Contact
-
Service d'hématologie clinique, département de greffe de moelle CHU Nice
NOT_YET_RECRUITINGNice, France
Contact
Contact
-
Service d'hématologie greffe Hôpital St Louis
NOT_YET_RECRUITINGParis, France
Contact
Contact
-
Service d'hématologie greffe Hôpital St Louis
NOT_YET_RECRUITINGPoitiers, France
Contact
Contact
-
Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-Ferrand
NOT_YET_RECRUITINGClermont-Ferrand, France
Contact
Contact
Contact
-
Service de thérapie cellulaire et l'hématologie clinique adulte CHU Limoges
NOT_YET_RECRUITINGLimoges, France
Contact
Contact
-
Service des Maladies du sang Hôpital HURIEZ, CHRU de Lille
NOT_YET_RECRUITINGLille, France
Contact
Contact
-
Service hématologie CHU Grenoble
NOT_YET_RECRUITINGGrenoble, France
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplantation (FMT) given as an enema
What this could lead to
If it works, this could offer a simple way to prevent serious complications after stem cell transplants, improving survival and quality of life for blood cancer patients.
What could go wrong
This is a mid-stage trial with 150 people, so results are not yet proven. FMT carries a small risk of infection or side effects, and the benefit may not be seen in all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.